Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

GREEN BAY – Finances remain strong at 1265 Lombardi Ave. The Packers reported an $83.7 million operating profit for the ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

The Bristol Myers Squibb-Pfizer Alliance today announced a new direct-to-patient option for purchasing Eliquis (apixaban) via ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...